Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| SEP-H5255 | Human | Human P-Selectin / CD62P Protein, Fc Tag |  |
|
|
| SEP-H52E4 | Human | Human P-Selectin / CD62P Protein, His Tag |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Crizanlizumab | Sel-G-1; SEG-101; SEG101; Sel-G1 | Approved | Selexys Pharmaceuticals Corp | Adakveo, Ryverna | United States | Anemia, Sickle Cell | Novartis Pharmaceuticals Corp | 2019-11-15 | Coronavirus Disease 2019 (COVID-19); Leukoencephalopathies; Primary Myelofibrosis; Priapism; Anemia, Sickle Cell | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Inclacumab | RO-4905417; RG-1512; LC-1004-002; R-1512; PF-07940370; LC1004-002; DSM ACC2641; DSM-ACC-2641; RO 4905417 | Phase 3 Clinical | Genmab A/S, F. Hoffmann-La Roche Ltd | Pain; Myocardial Infarction; Graft Occlusion, Vascular; Anemia, Sickle Cell; Peripheral Arterial Disease | Details |
This web search service is supported by Google Inc.
A-Z
